Charles Ryan

Charles S.
Ryan is Chief Executive Officer at Quince Therapeutics SpA since 2023.
Holds director positions at GlycoMira LLC and Polaryx Therapeutics, Inc. (starting 2026).
Member of the New York State Bar Association and Trustee at The College of Wooster.
Formerly President, Chief Executive Officer & Director at Orthobond Corp.
(2016–2018).
Chief Executive Officer & Director at Neurotrope, Inc. and TAO Synergies, Inc. (2018–2020).
Chief Executive Officer & Director at Petros Pharmaceuticals, Inc. Chairman, President & Chief Executive Officer at Travecta Therapeutics Pte Ltd. (2017–2022).
Chairman-Development Council at Stony Brook University Medical Center.
Independent Director at BNB Plus Corp.
(2011–2019) and BioRestorative Therapies, Inc. (2015–2020).
Director at New York Biotechnology Association, Inc., ABS Materials, Inc., GlycoMira Therapeutics, Inc. Vice President & General Counsel at Cold Spring Harbor Laboratory, Inc. (2015–2016).
President at Quince Therapeutics, Inc. (2023–2026).
Chief Intellectual Property Counsel & Senior VP at Forest Laboratories, Inc. (2003–2014).
Vice President & General Counsel at Engelhard Long Island, Inc. (1998–2002).
Chief Operating Officer at LAB21, Inc. (2002–2003).
Trustee at Western New England University.
Education includes a doctorate from Stony Brook University (1990), graduate degree from Western New England University School of Law (1993), and undergraduate degree from The College of Wooster (1986).